PUMA BIOTECHNOLOGY, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$18.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- PUMA BIOTECHNOLOGY, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$18.70M.
- PUMA BIOTECHNOLOGY, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$25.30M.
- PUMA BIOTECHNOLOGY, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$6.20M.
- PUMA BIOTECHNOLOGY, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$5.10M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$18.70M 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$25.30M 10-K · filed 2025-02-27 | |
| 2023-12-31 | -$6.20M 10-K · filed 2024-02-29 | |
| 2022-12-31 | -$5.10M 10-K · filed 2024-02-29 | |
| 2021-12-31 | -$12.50M 10-K · filed 2023-03-02 | $12.50M 10-K · filed 2022-03-03 |
| 2020-12-31 | $8.70M 10-K · filed 2022-03-03 | |
| 2019-12-31 | $14.20M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $5.50M 10-K · filed 2020-02-28 | |
| 2017-12-31 | $48.10M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $106.20M 10-K · filed 2018-03-09 | |
| 2015-12-31 | $101.40M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $49.80M 10-K · filed 2016-02-29 | |
| 2013-12-31 | $25.30M 10-K · filed 2015-03-02 | |
| 2012-12-31 | $29.20M 10-K · filed 2014-03-03 | |
| 2011-12-31 | $4.10M 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |